These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22873129)

  • 1. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines.
    Alving CR; Rao M; Steers NJ; Matyas GR; Mayorov AV
    Expert Rev Vaccines; 2012 Jun; 11(6):733-44. PubMed ID: 22873129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants.
    Alving CR
    Immunobiology; 1993 Apr; 187(3-5):430-46. PubMed ID: 8330907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy.
    Fries LF; Gordon DM; Richards RL; Egan JE; Hollingdale MR; Gross M; Silverman C; Alving CR
    Proc Natl Acad Sci U S A; 1992 Jan; 89(1):358-62. PubMed ID: 1729706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions.
    Ulrich JT; Myers KR
    Pharm Biotechnol; 1995; 6():495-524. PubMed ID: 7551233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs.
    Matyas GR; Mayorov AV; Rice KC; Jacobson AE; Cheng K; Iyer MR; Li F; Beck Z; Janda KD; Alving CR
    Vaccine; 2013 Jun; 31(26):2804-10. PubMed ID: 23624097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of liposome-polycation-DNA(LPD) and monophosphoryl lipid A(MPL) adjuvant formulations in BALB/c mice models.
    Zhang XP; Cui WH
    Immunol Invest; 2012; 41(4):356-66. PubMed ID: 21864115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines.
    Baldridge JR; Crane RT
    Methods; 1999 Sep; 19(1):103-7. PubMed ID: 10525445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly effective generic adjuvant systems for orphan or poverty-related vaccines.
    Rao M; Peachman KK; Li Q; Matyas GR; Shivachandra SB; Borschel R; Morthole VI; Fernandez-Prada C; Alving CR; Rao VB
    Vaccine; 2011 Jan; 29(5):873-7. PubMed ID: 21115053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomes containing lipid A: a potent nontoxic adjuvant for a human malaria sporozoite vaccine.
    Alving CR; Richards RL
    Immunol Lett; 1990 Aug; 25(1-3):275-9. PubMed ID: 2283158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal adjuvants for human vaccines.
    Alving CR; Beck Z; Matyas GR; Rao M
    Expert Opin Drug Deliv; 2016 Jun; 13(6):807-16. PubMed ID: 26866300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a leishmaniasis vaccine: the importance of MPL.
    Reed SG; Coler RN; Campos-Neto A
    Expert Rev Vaccines; 2003 Apr; 2(2):239-52. PubMed ID: 12899575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
    Evans JT; Cluff CW; Johnson DA; Lacy MJ; Persing DH; Baldridge JR
    Expert Rev Vaccines; 2003 Apr; 2(2):219-29. PubMed ID: 12899573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New hepatitis B vaccine formulated with an improved adjuvant system.
    Kundi M
    Expert Rev Vaccines; 2007 Apr; 6(2):133-40. PubMed ID: 17408363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of monophosphoryl lipid A derivatives as fully synthetic self-adjuvanting glycoconjugate cancer vaccine carriers.
    Zhou Z; Mondal M; Liao G; Guo Z
    Org Biomol Chem; 2014 May; 12(20):3238-45. PubMed ID: 24728423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.
    Garçon N; Van Mechelen M
    Expert Rev Vaccines; 2011 Apr; 10(4):471-86. PubMed ID: 21506645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid tucaresol as an adjuvant for methamphetamine vaccine development.
    Collins KC; Schlosburg JE; Lockner JW; Bremer PT; Ellis BA; Janda KD
    Chem Commun (Camb); 2014 Apr; 50(31):4079-81. PubMed ID: 24615284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy.
    Cooper C; Mackie D
    Expert Rev Vaccines; 2011 Apr; 10(4):417-27. PubMed ID: 21506639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status.
    Korsholm KS; Andersen PL; Christensen D
    Expert Rev Vaccines; 2012 May; 11(5):561-77. PubMed ID: 22827242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvants for vaccines to drugs of abuse and addiction.
    Alving CR; Matyas GR; Torres O; Jalah R; Beck Z
    Vaccine; 2014 Sep; 32(42):5382-9. PubMed ID: 25111169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.